Involvement of lncRNAs in the tumor microenvironment:a new property of tumor immunity

作     者：Qingyu Lin Jiaqi Zhu Ying Hu Qingyu Lin;Jiaqi Zhu;Ying Hu

作者机构：School of Life Science and TechnologyHarbin Institute of TechnologyHarbin 150001China Zhengzhou Research Institute of Harbin Institute of TechnologyZhengzhou 450000China Key Laboratory of Science and Engineering for the Multi-modal Prevention and Control of Major Chronic DiseasesMinistry of Industry and Information TechnologyZhengzhou 450000China School of AstronauticsHarbin Institute of TechnologyHarbin 150001China 

出 版 物：《Cancer Biology & Medicine》 (癌症生物学与医学（英文版）)

年 卷 期：2023年第20卷第8期

页      面：553-561页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：supported by the National Nature Science Foundation(Grant Nos.82150115,82025027,and 32000517) the National Key R&D Program of China(Grant No.2022YFA1105200) 

主　　题：immunity death patients 

摘      要：Immune checkpoint blockade(ICB)has achieved durable clinical responses and has significantly improved the overall survival of cancer *** the ICB agents,programmed death 1(PD-1)/programmed death ligand 1(PD-L1)antibodies are used to treat various human tumors by blocking PD-1/PD-L1 *** response rates with low autoimmune toxicity have been reported in 20%–30%of non-selected patients1;however,most patients fail to respond to PD-1/PD-L1 blockade or acquire resistance during therapy through unknown mechanisms1.